β蛋白升高的MCI受试者阿尔茨海默病的差异风险

IF 3.6 3区医学 Q1 CLINICAL NEUROLOGY Journal of the Neurological Sciences Pub Date : 2024-11-23 DOI:10.1016/j.jns.2024.123319

Bin Zhou, Masanori Fukushima, The Alzheimer's Disease Neuroimaging Initiative

{"title":"β蛋白升高的MCI受试者阿尔茨海默病的差异风险","authors":"Bin Zhou, Masanori Fukushima, The Alzheimer's Disease Neuroimaging Initiative","doi":"10.1016/j.jns.2024.123319","DOIUrl":null,"url":null,"abstract":"<div><h3>Backgrounds</h3><div>People with elevated beta amyloid have different risk and progress speed to Alzheimer's disease.</div></div><div><h3>Purpose</h3><div>The research is to validate the risk classification of AD developed in the Shanghai mild cognitive impairment (MCI) cohort study using ADNI data.</div></div><div><h3>Methods</h3><div>The risk classification of AD in MCI was based on several optimal cut-off points of a novel parameter Cog_Vol.</div></div><div><h3>Results</h3><div>In total, 843 subjects with MCI were included, of whom 220 had elevated PET beta amyloid. 273 (32.3 %) and 70 (31.8 %) progressed to AD in all subjects and in those with elevated PET beta amyloid, respectively. The risk of AD in subjects whose Cog_Vol >340 was very low, while the risk for those with Cog_Vol less than 101 indicated a super high within 4 years of follow-up.</div></div><div><h3>Discussion</h3><div>Risk classification using Cog_Vol at an optimal value was able to detect subjects among those with PET-amyloid-elevated MCI were at greater risk of developing AD and were unlikely to develop AD within 4 years of follow-up.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"467 ","pages":"Article 123319"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Differential risk of Alzheimer's disease in MCI subjects with elevated Abeta\",\"authors\":\"Bin Zhou, Masanori Fukushima, The Alzheimer's Disease Neuroimaging Initiative\",\"doi\":\"10.1016/j.jns.2024.123319\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Backgrounds</h3><div>People with elevated beta amyloid have different risk and progress speed to Alzheimer's disease.</div></div><div><h3>Purpose</h3><div>The research is to validate the risk classification of AD developed in the Shanghai mild cognitive impairment (MCI) cohort study using ADNI data.</div></div><div><h3>Methods</h3><div>The risk classification of AD in MCI was based on several optimal cut-off points of a novel parameter Cog_Vol.</div></div><div><h3>Results</h3><div>In total, 843 subjects with MCI were included, of whom 220 had elevated PET beta amyloid. 273 (32.3 %) and 70 (31.8 %) progressed to AD in all subjects and in those with elevated PET beta amyloid, respectively. The risk of AD in subjects whose Cog_Vol >340 was very low, while the risk for those with Cog_Vol less than 101 indicated a super high within 4 years of follow-up.</div></div><div><h3>Discussion</h3><div>Risk classification using Cog_Vol at an optimal value was able to detect subjects among those with PET-amyloid-elevated MCI were at greater risk of developing AD and were unlikely to develop AD within 4 years of follow-up.</div></div>\",\"PeriodicalId\":17417,\"journal\":{\"name\":\"Journal of the Neurological Sciences\",\"volume\":\"467 \",\"pages\":\"Article 123319\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022510X24004556\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022510X24004556","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景β -淀粉样蛋白升高的人群患阿尔茨海默病的风险和进展速度不同。目的利用ADNI数据验证上海轻度认知障碍（MCI）队列研究中AD的风险分类。方法基于新参数Cog_Vol的几个最优截断点对MCI患者AD的风险进行分类。结果共纳入843例轻度认知损伤患者，其中PET - β淀粉样蛋白升高220例。所有受试者中273例（32.3%）和70例（31.8%）进展为AD， PET β淀粉样蛋白升高的受试者中分别有273例（32.3%）和70例（31.8%）进展为AD。Cog_Vol >；340的受试者患AD的风险非常低，而Cog_Vol < 101的受试者在随访4年内患AD的风险非常高。使用Cog_Vol的最佳值进行风险分类能够检测出pet -淀粉样蛋白升高的MCI患者患AD的风险更高，并且在随访4年内不太可能患AD。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Differential risk of Alzheimer's disease in MCI subjects with elevated Abeta

Backgrounds

People with elevated beta amyloid have different risk and progress speed to Alzheimer's disease.

Purpose

The research is to validate the risk classification of AD developed in the Shanghai mild cognitive impairment (MCI) cohort study using ADNI data.

Methods

The risk classification of AD in MCI was based on several optimal cut-off points of a novel parameter Cog_Vol.

Results

In total, 843 subjects with MCI were included, of whom 220 had elevated PET beta amyloid. 273 (32.3 %) and 70 (31.8 %) progressed to AD in all subjects and in those with elevated PET beta amyloid, respectively. The risk of AD in subjects whose Cog_Vol >340 was very low, while the risk for those with Cog_Vol less than 101 indicated a super high within 4 years of follow-up.

Discussion

Risk classification using Cog_Vol at an optimal value was able to detect subjects among those with PET-amyloid-elevated MCI were at greater risk of developing AD and were unlikely to develop AD within 4 years of follow-up.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the Neurological Sciences 医学-临床神经学

CiteScore

7.60

自引率

2.30%

发文量

313

审稿时长

22 days

期刊介绍： The Journal of the Neurological Sciences provides a medium for the prompt publication of original articles in neurology and neuroscience from around the world. JNS places special emphasis on articles that: 1) provide guidance to clinicians around the world (Best Practices, Global Neurology); 2) report cutting-edge science related to neurology (Basic and Translational Sciences); 3) educate readers about relevant and practical clinical outcomes in neurology (Outcomes Research); and 4) summarize or editorialize the current state of the literature (Reviews, Commentaries, and Editorials). JNS accepts most types of manuscripts for consideration including original research papers, short communications, reviews, book reviews, letters to the Editor, opinions and editorials. Topics considered will be from neurology-related fields that are of interest to practicing physicians around the world. Examples include neuromuscular diseases, demyelination, atrophies, dementia, neoplasms, infections, epilepsies, disturbances of consciousness, stroke and cerebral circulation, growth and development, plasticity and intermediary metabolism.